Polypid Stock Today
| PYPD Stock | USD 2.98 0.04 1.36% |
PerformanceModest
| Odds Of DistressHigh
|
PolyPid is trading at 2.98 as of the 15th of March 2025, a 1.36 percent increase since the beginning of the trading day. The stock's lowest day price was 2.83. PolyPid has a very high chance of experiencing financial distress in the next few years of operation. It also did not have a very good performance during the last 90 trading days. The performance scores are derived for the period starting the 15th of December 2024 and ending today, the 15th of March 2025. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 26th of June 2020 | Category Healthcare | Classification Health Care |
PolyPid Ltd., a late-stage biopharma company, develops, manufactures, and commercializes products based on polymer-lipid encapsulation matrix platform to address unmet medical needs. PolyPid Ltd. was incorporated in 2008 and is headquartered in Petah Tikva, Israel. The company has 10.19 M outstanding shares of which 6.94 K shares are at this time shorted by private and institutional investors with about 0.62 trading days to cover. More on PolyPid
Moving against PolyPid Stock
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
PolyPid Stock Highlights
ESG Sustainability
Environmental | Governance | Social |
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, NASDAQ Health Care, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsPolyPid can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand PolyPid's financial leverage. It provides some insight into what part of PolyPid's total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||
PolyPid (PYPD) is traded on NASDAQ Exchange in USA. It is located in 18 Hasivim Street, Petah Tikva, Israel, 4959376 and employs 57 people. PolyPid is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Micro-Cap' category with a current market capitalization of 30.32 M. PolyPid conducts business under Biotechnology sector and is part of Health Care industry. The entity has 10.19 M outstanding shares of which 6.94 K shares are at this time shorted by private and institutional investors with about 0.62 trading days to cover.
PolyPid currently holds about 23.78 M in cash with (21.96 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.22.
Check PolyPid Probability Of Bankruptcy
Ownership AllocationThe market capitalization of PolyPid is $30.32 Million. Over half of PolyPid's outstanding shares are owned by third-party entities. These third-party entities are typically referred to as corporate investors that secure positions in a given instrument to benefit from reduced trade commissions. Note, that even with negative profits, if the true value of the company is larger than the current market value, you may still be able to generate positive returns on investment in this company.
Check PolyPid Ownership Details
PolyPid Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Advisor Group Holdings, Inc. | 2024-12-31 | 467 | |
| Ubs Group Ag | 2024-12-31 | 4.0 | |
| Sbi Securities Co Ltd | 2024-12-31 | 1.0 | |
| Golden State Equity Partners | 2024-12-31 | 0.0 | |
| Rosalind Advisors, Inc. | 2024-12-31 | 1 M | |
| Aigh Capital Management, Llc | 2024-12-31 | 827.9 K | |
| Dafna Capital Management Llc | 2024-12-31 | 291.3 K | |
| J. Goldman & Co Lp | 2024-12-31 | 128.5 K | |
| Stonepine Capital Management Llc | 2024-12-31 | 103.7 K | |
| Adar1 Capital Management Llc | 2024-12-31 | 80.1 K | |
| Yelin Lapidot Holdings Management Ltd | 2024-12-31 | 11.2 K |
PolyPid Historical Income Statement
PolyPid Stock Against Markets
PolyPid Corporate Management
| Ori Warshavsky | Chief US | Profile | |
| Dikla Akselbrad | Chief Officer | Profile | |
| Malka Reichart | Scientific Director | Profile | |
| Rivi Levari | Vice Resource | Profile | |
| Orna Blum | Legal Counsel | Profile | |
| JeanMarc PharmD | Chief Officer | Profile | |
| Tal Vilnai | General Secretary | Profile |
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in PolyPid. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey. For information on how to trade PolyPid Stock refer to our How to Trade PolyPid Stock guide.You can also try the Positions Ratings module to determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of PolyPid. If investors know PolyPid will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about PolyPid listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of PolyPid is measured differently than its book value, which is the value of PolyPid that is recorded on the company's balance sheet. Investors also form their own opinion of PolyPid's value that differs from its market value or its book value, called intrinsic value, which is PolyPid's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because PolyPid's market value can be influenced by many factors that don't directly affect PolyPid's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between PolyPid's value and its price as these two are different measures arrived at by different means. Investors typically determine if PolyPid is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, PolyPid's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.